These findings underscore the promise of ALI culture in advancing skin organoid engineering, offering a sophisticated and functional platform for research and therapeutic development in dermatology.

These findings underscore the promise of ALI culture in advancing skin organoid engineering, offering a sophisticated and functional platform for research and therapeutic development in dermatology.

This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid disease model to enter clinical trials, and the first targeted therapy candidate to ...